



World Health Organization

Global Hepatitis Programme

Guideline development for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B

PICO QUESTIONS for the WHO Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; E-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

PICO questions

PICO 1a Vaccination	Among persons at high risk of acquisition of hepatitis B, what are the most effective hepatitis B screening and vaccination strategies?
P	Household and sexual contacts of HBsAg-positive persons (includes HIV-infected and HIV-negative or unknown HIV status)
I	Different active screening and hepatitis B vaccination strategies
C	No active screening or HBV vaccination
O	New HBsAg-positive transmissions among contacts; identification of existing HBsAg-positive cases; number of cases referred for care; number of cases referred for vaccination; number completed vaccination course; number hepatitis B immune; potential harms of screening (disclosure, stigmatization); cost; cost-effectiveness

PICO 1b Vaccination	Among HIV-infected persons, what are the most effective hepatitis B vaccination strategies?
P	HIV-positive adults, adolescents and children
I	Any hepatitis B vaccination strategy (e.g. double dose, additional booster doses, decreased dose interval)
C	Any hepatitis B vaccination strategy (including different time intervals) or no vaccination
O	Immunogenicity (sAb titre); HBV DNA positivity; HBeAg seropositivity; HBsAg seropositivity; adverse events of vaccination (any); cost-effectiveness

PICOT 2a Who to Treat?	Among HBsAg-positive persons, what factors/tests best identify individuals at highest risk of progression, as well as those at very low risk of progression?
P	HBsAg-positive persons
I	Key permutations of key baseline risk factors from studies of prognosis: clinical factors only (age, cirrhosis/fibrosis); clinical plus ALT: clinical plus ALT and HBV DNA: Sample stratifications include: age >40 vs <40 years; HBeAg-positive vs -negative; cirrhosis (compensated or decompensated) vs no cirrhosis; fibrosis (METAVIR 1-3) vs no fibrosis; HBV DNA (any positive or unknown, or >2000 or >20 000 IU/mL or >10 ⁶ copies/mL) vs undetectable; ALT (>2x ULN or >ULN) vs normal
C	Absence of these baseline factors
O	Liver-related morbidity (fibrosis, cirrhosis, end-stage liver disease, hepatocellular carcinoma); progression of liver disease; mortality
T	Annual progression and mortality

PICOT 2b Who to Treat?	Among HBsAg-positive persons, what factors/tests best identify individuals with greatest benefit of treatment, and least benefit from treatment in those with and without access to laboratory tests?
P	HBsAg-positive persons stratified according to key baseline prognostic factors and : clinical factors only (age, cirrhosis/fibrosis); clinical plus ALT: clinical plus ALT and HBV DNA: sample stratifications include: Age >40 vs <40 years; HBeAg positive vs. negative; cirrhosis (compensated or decompensated) vs no cirrhosis; Fibrosis (METAVIR 1-3) vs no fibrosis; HBV DNA (any positive or unknown, or >2000 or >20 000 IU/mL or >10 ⁶ copies/mL) vs undetectable; ALT (>2x ULN or >ULN) vs normal
I	HBV antiviral treatment
C	No HBV treatment
O	HBeAg seroconversion; HBsAg loss; undetectable HBV DNA; liver-related morbidity (fibrosis, cirrhosis, end-stage liver disease); progression of liver disease;

	reversion of fibrosis stage; mortality; severe adverse effects; antiviral resistance
T	Annual progression and mortality

PICOT 3a What treatment to use?	What is the most effective regimen for the treatment of chronic hepatitis B infection?
P	Treatment-naïve HBsAg-positive persons (stratified by HIV status, and different permutations of baseline risk factors from treatment studies, including HBeAg status, present or absence of cirrhosis, fibrosis stage, HBV DNA level)
I	HBV treatment with highly active medicines and a high barrier to resistance (tenofovir and entecavir)
C	HBV treatment with other medicines with a low barrier to resistance (lamivudine, telbivudine or adefovir)
O	HBeAg seroconversion; HBsAg loss; undetectable HBV DNA; liver-related morbidity (fibrosis, cirrhosis, end-stage liver disease); progression of liver disease; reversion of fibrosis stage; mortality; severe adverse effects; antiviral resistance; cost; cost-effectiveness
T	Annual progression and mortality

PICOT 3b Management of treatment failure	What is the most effective regimen for management of treatment failure?
P	HBsAg-positive persons previously treated with HBV regimens with a low barrier to resistance (lamivudine, telbivudine or adefovir)
I	HBV treatment with highly active medicines and a high barrier to resistance (tenofovir and entecavir)
C	Continuation of HBV treatment regimens with a low barrier to resistance (lamivudine, telbivudine or adefovir)
O	Liver-related morbidity (fibrosis, cirrhosis, end-stage liver disease); progression of liver disease; reversion of fibrosis stage; mortality; HBeAg seroconversion; HBsAg loss; undetectable HBV DNA; severe adverse effects; antiviral resistance; cost; cost-effectiveness
T	Annual progression and mortality

PICOT 4 Treatment duration	What criteria should be used to decide when to stop treatment?
P	HBsAg-positive persons receiving HBV treatment
I	Different criteria for discontinuation of HBV treatment (HBeAg seroconversion, HBsAg loss, undetectable HBV DNA)
C	Continuation of HBV treatment for 1, 2, 3, 4, 5 years or more
O	Liver-related morbidity (fibrosis, cirrhosis, end-stage liver disease); progression of liver disease; mortality; HBeAg reversion and hepatitis flare; severe adverse effects; antiviral resistance

PICOT 5a Monitoring	What is the optimal frequency of monitoring for disease progression?
P	HBsAg-positive persons stratified according to baseline disease stage (cirrhosis, fibrosis stage, eAg status, HIV status)
I	Annual clinical evaluation or symptom-based referral
C	Six-monthly comprehensive evaluation with fibrosis assessment, ALT, eAg status and HBV DNA
O	Liver-related morbidity (fibrosis, cirrhosis, end-stage liver disease); progression

	of liver disease; mortality at different time points
--	--

PICOT 5b Monitoring	What is the optimal nature and frequency of monitoring for toxicity in patients receiving tenofovir?
P	HBsAg-positive persons receiving tenofovir stratified by age, gender, pregnancy status, HIV status and baseline disease stage (cirrhosis, fibrosis stage)
I	Symptom-based referral versus laboratory/other monitoring
C	Laboratory/other monitoring
O	Renal impairment, bone mineral density decline (osteoporosis, osteopenia)

PICOT 6 Monitoring for HCC	What is the most effective monitoring strategy to identify HCC early in people with chronic HBV?
P	People with chronic hepatitis B viral infection, defined by the persistence of HBsAg for more than six months
I	Screening using the following methods or combinations: liver ultrasound scan (USS); serum alpha-fetoprotein (AFP); liver USS and serum AFP
C	The screening interventions listed above or no intervention
O	New diagnosis of hepatocellular carcinoma; disease-specific mortality; all-cause mortality; lesion or hepatocellular carcinoma size (< 3cm in diameter; ≥ 3cm in diameter); liver cancer stage; cost-effectiveness

PICOT 7 PMTCT	What is the most effective antiviral therapy during the third trimester of pregnancy, to reduce transmission of HBsAg?
P	Pregnant women in the third trimester of pregnancy (defined as 27–40 weeks gestation) with chronic hepatitis B virus infection (positive for HBsAg persistently for more than 6 months) (stratified by HBeAg status)
I	Maternal treatment with the following drugs or drug combinations during third trimester of pregnancy (with or without use of birth dose vaccine): tenofovir; lamivudine; telbivudine; emtricitabine plus tenofovir/tenofovir plus emtricitabine; entecavir; adefovir
C	Interventions listed above versus each other (either as monotherapy or combination therapy), placebo or no intervention
O	Newborn (0–9 months) and infant (9–15 first months) HBV DNA positivity; newborn and infant HBeAg seropositivity; newborn and infant HBsAg seropositivity; congenital abnormalities; adverse events (maternal (any); infant (any); infant (serious adverse events); cost-effectiveness

PICOT 8 Non-invasive assessment of liver disease stage	How should staging of liver disease be carried out in persons with HBV infection?
P	Persons with chronic hepatitis B infection
I	Non-invasive assessment of liver fibrosis using FIB-4, APRI (AST-to-platelet index), FibroTest or FibroScan
C	Liver biopsy
O	Diagnostic accuracy of non-invasive tests for staging fibrosis